Omeros Corporation

Omeros Corporation develops small-molecule and protein therapeutics targeting immunologic diseases. Products include Narsoplimab for TA-TMA, IgAN, and COVID-19; OMS1029 for lectin pathway disorders; OMS906 for Paroxysmal nocturnal hemoglobinuria and alternative pathway disorders; and OMS527 for addictions, compulsive disorders, and movement disorders. MASP-2 is a pro-inflammatory protein target for lectin pathway disorders. MASP-3 small-molecule inhibitors treat alternative pathway disorders. The company also develops Adoptive T-Cell, CAR T-Cell, Immunomodulators/Immunotoxins/Cancer Vaccines for various cancers.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

3.2 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0